CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.
about
An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Genetic determinants of response to warfarin during initial anticoagulationToward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interactionInteraction of warfarin with drugs, natural substances, and foods.Enzyme Polymorphism in Warfarin Dose Management After Pediatric Cardiac Surgery.The pharmacogenetics of coumarin therapy.Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial.Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.A Bayesian dose-individualization method for warfarin.An acenocoumarol dose algorithm based on a South-Eastern European population.A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol.Comparison of the TaqMan and LightCycler systems in pharmacogenetic testing: evaluation of CYP2C9*2/*3 polymorphisms.
P2860
Q30558676-1CBCFC5E-07EF-4803-BA96-3174BC1FA7BFQ34252907-A5E4EC04-A435-4364-9439-6135633B584FQ34759038-8ABCDED5-1491-4985-9439-C01DEE968BBAQ35873687-DB2C4942-3F12-43E5-8D6E-E95DA025E35FQ35880928-556F781A-9812-447B-BFC6-0E7F32D97E65Q36007599-FFF30EC0-D352-46C7-B53D-428B91EDB362Q36118277-6B81D9BF-7AE7-457F-8537-74BCA9DFC90AQ36192806-D3C0F646-10D1-4BA6-80BC-959D8BE34B9DQ36195396-F4B5E72D-4BF8-4A98-B565-402604202476Q39471514-3EAD9899-9900-485B-A2E4-0ED819388063Q39483373-BBF3E925-5D10-477E-B972-51ECE743788AQ44899072-7BA4CF5B-5951-4223-8D1F-844DA4C732FEQ50775104-C428CA28-FEAE-4DFC-AA05-1E62BEE9E63FQ51739644-8EF52C96-F4C8-4299-B287-E8FA09FB36E8Q53233863-DEB3AF1C-3903-4973-B261-C41F17609B01Q54615022-0F1B2D32-E9A2-4D31-885C-04D98DA35F3F
P2860
CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
CYP2C9 and oral anticoagulatio ...... similarities yet differences.
@ast
CYP2C9 and oral anticoagulatio ...... similarities yet differences.
@en
type
label
CYP2C9 and oral anticoagulatio ...... similarities yet differences.
@ast
CYP2C9 and oral anticoagulatio ...... similarities yet differences.
@en
prefLabel
CYP2C9 and oral anticoagulatio ...... similarities yet differences.
@ast
CYP2C9 and oral anticoagulatio ...... similarities yet differences.
@en
P2093
P1476
CYP2C9 and oral anticoagulatio ...... similarities yet differences.
@en
P2093
Grant R Wilkinson
Harumi Takahashi
Hirotoshi Echizen
Roberto Padrini
P304
P356
10.1016/J.CLPT.2004.01.007
P407
P577
2004-05-01T00:00:00Z